 Molecular diagnostics company Genetic Technologies Limited ASX: GTG, NASDAQ: GENE is pleased to advise that its third-generation breast cancer test GeneType for Breast Cancer is on track for commercial release in the Unites States US in Q1 2020. Genetic Technologies expects to take advantage of the growing confidence and interest in genomic testing, and its first to market status in the US market. GeneType for breast cancer BC is on track for release in the US in Q1 2020 via a soft launch across 20 centres in 8 States, which demonstrates the strong support from practitioners for the introduction of the companys third generation test incorporating mammography data. 